Libbs stops sales of chronic migraine medication in Brazil

The pharmaceutical company Libbs announced the discontinuation of Emgality, a medicine used to treat chronic migraines, on the Brazilian market. The decision was communicated to Anvisa on May 4th. The company did not detail the specific reasons that led to the closure of operations with the drug.
In an official statement, Libbs reported that the measure occurs “due to a portfolio update”. The medicine, marketed in partnership with Eli Lilly, which holds the patent, leaves the market after almost seven years of regulatory approval in the country.
Fármaco approved over six years ago
Emgality received authorization from Anvisa in November 2019. The drug’s active ingredient is galcanezumab, a molecule that acts to reduce the frequency and intensity of chronic migraine attacks in adult patients. Desde was then available for medical prescription and commercialization in Brazilian pharmacies.
Chronic migraine affects approximately 2% of the world’s population. No Brasil, it is estimated that around 15 million people suffer from some form of migraine, with chronic migraines being responsible for significant impacts on patients’ quality of life and professional productivity. Medicamentos like Emgality represented an important therapeutic option for refractory cases.
Discontinuation of Emgality does not immediately affect patients undergoing treatment. Aqueles who use the drug will be able to continue using their current stocks. Contudo, after the end of sales by Libbs, new patients will no longer have access to the medicine through prescription on Brasil.

Impacto for patients undergoing treatment
Pacientes who depend on Emgality will have to seek therapeutic alternatives from their doctors. The Brazilian market offers other options for the treatment of chronic migraine, including medications with similar mechanisms of action and different pharmacological approaches. The medical decision about which medication to use must consider specific characteristics of each patient.
Existem other injectable molecules approved by Anvisa for chronic migraine:
- Anticorpos monoclonal against CGRP (calcitonin gene-related peptide)
- Medicamentos preventive orals of different therapeutic classes
- Terapias intravenous for more severe cases
- Tratamentos with botulinum toxin approved specifically for migraine
The transition to new medications requires medical monitoring. Alguns patients may have a better response to one drug compared to another, which is why individualized assessment is essential. Além Furthermore, issues related to health plan coverage and reimbursement policies can influence therapeutic choice.
Contexto from discontinuation
The pharmaceutical company Libbs did not disclose detailed information about factors that led to the discontinuation. Empresas of pharmaceuticals frequently make adjustments to their portfolios for commercial, financial or strategic reasons. Analysis of sales performance, market perspectives and alignment with corporate objectives are part of these decisions.
Brasil represents a significant market for pharmaceuticals, but certain pharmaceuticals may be in lower demand compared to other geographies. The concentration of resources on medicines with higher sales volume or higher profit margins is a common practice in the pharmaceutical sector.
Eli Lilly, owner of the formula, maintains operations in other markets. The specific decision to discontinue Brasil does not necessarily imply the global closure of Emgality. Diferentes commercial strategies can be adopted in each country according to local analysis.
Reações in the healthcare sector
The medical community awaits official communications from Libbs and potential guidance from Anvisa regarding the transition. Associações from patients and organizations focused on neurology may speak out about the impact of this discontinuation. Anvisa, as a regulatory body, monitors access to medicines and possible therapeutic gaps in the market.
Profissionais who prescribe Emgality will need to update treatment protocols and inform their patients of the changes. Clear communication between doctors and patients is essential to ensure continuity of care and avoid abrupt interruptions in treatment.
Nenhum public statement from medical or patient rights organizations had been released at press time. The community awaits positions that better contextualize the implications of the measure for people with chronic migraines in Brasil.






